Corixa (company)
U.S. biotechnology/pharmaceutical company
From Wikipedia, the free encyclopedia
Corixa was a biotechnology/pharmaceutical company based in Seattle, Washington, involved in the development of immunotherapeutics to combat autoimmune diseases, infectious diseases, and cancer. It was founded in 1994. It operated a laboratory and production facility in Hamilton, Montana.
Company type
biotechnology/pharmaceuticalFounded1994 in Seattle, Washington
DefunctMarch 31, 2006
Successoracquired by GlaxoSmithKline
 | |
Company type | biotechnology/pharmaceutical |
|---|---|
| Founded | 1994 in Seattle, Washington |
| Defunct | March 31, 2006 |
| Successor | acquired by GlaxoSmithKline |
| Headquarters | Seattle , Washington |
Number of locations | 2 |
| Parent | GlaxoSmithKline (United States)  |
In 2005, the European pharmaceuticals giant GlaxoSmithKline completed the acquisition of Corixa.[1] GSK had formerly made use of the Corixa's MPL (Monophosphoryl lipid A, a derivative of the lipid A molecule), an adjuvant in some of their vaccines.
External links
- "Corixa Corporation - powering the immune system". Archived from the original on 2006-03-01.
